Shares of Atricure Inc. (ATRC) soared 38 percent to $7.20, the highest intraday price since October 2008, after the maker of medical devices said the Food and Drug Administration cleared its AtriClip system, which is designed for use in surgery treating atrial fibrillation.
“Clearance of the AtriClip system in the United States represents a major product and clinical milestone for AtriCure,” David J. Drachman, AtriCure’s President and CEO said in a statement. “We believe that the AtriClip system provides a safe and efficient method to exclude the left atrial appendage. This key innovation represents a large and exciting new growth platform and demonstrates our steadfast commitment to developing market leading technologies to meet the needs of patients and physicians.”
The approval allows the West Chester, Ohio-based company to market the device for use in open heart surgeries.
ATRC gained $1.37, or 26.26%, to $6.60 rtq at 11:49 E.T. in Nasdaq trading.